Book a Meeting

Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ107] (CAT#: BioBet-107ZP) Datasheet

Target
CD19
Isotype
Human Therapeutic Antibody
Description
ADCC-enhanced denintuzumab mafodotin is a non-fucosylated anti-CD19 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-CD19 denintuzumab mafodotin, a biobetter by reducing fucosylation of the Fc region of denintuzumab mafodotin, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Cancers
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 Molecule
Background
CD19 (CD19 Molecule) is a Protein Coding gene.
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers.
Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.
Alternative Names
CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
Gene ID
930
UniProt ID
P15391
Cellular Localization
Plasma membrane
HGNC
1633
Ensembl
ENSG00000177455
OMIM
107265
Involvement in Disease
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Related Pathways
Its related pathways are RET signaling and B cell receptor signaling pathway (KEGG).
Function
As a co-receptor of b cell antigen receptor complex (BCR) on b lymphocytes. Lower the threshold of downstream signaling pathway activation and trigger b-cell response to antigen (PubMed: 2463100, PubMed: 1373518, PubMed: 16672701). Activating the signaling pathway leads to the activation of phosphatidylinositol 3-kinase and mobilization of intracellular Ca(2+) storage (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701). Not needed in the early steps of bone marrow B cell differentiation (PubMed:9317126). Necessary for normal differentiation of B-1 cells (similarity). Normal B cell differentiation and proliferation are required to respond to antigen challenges (PubMed: 2463100, PubMed: 1373518). Requires normal levels of serum immunoglobulins, and high-affinity antibodies produced upon antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701). 发送反馈 历史记录
Field of research
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Post-translational modifications
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Trade name
denintuzumab mafodotin
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Human Therapeutic Antibody
Antibody Clone
denintuzumab mafodotin
Description
Recombinant Humanized antibody to Human CD19
Indication
Cancers

Cancers

Related Products

Non-Fucosylated Anti-Human CD19 (MDX-1342) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1811ZP)
BetterBet™ Anti-CD19 Recycling Antibody (CAT#: AES-0622-ZP48)
Non-Fucosylated Anti-Human CD19 (3649-aFuc) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1674ZP)
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody, a biobetter (CAT#: BioBet-CB-010LX)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ106] (CAT#: BioBet-106ZP)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ102] (CAT#: BioBet-102ZP)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ100] (CAT#: BioBet-100ZP)
Non-Fucosylated Anti-Human CD19 (4G7) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1693ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany